Biblio
“2, 3, 7, 8-Tetrachlorodibenzo-p-dioxin suppresses tumor necrosis Factor-$\alpha$ and Anti-CD40–Induced Activation of NF-$ąppa$B/Rel in dendritic cells: p50 Homodimer Activation is not affected”, Molecular pharmacology, vol. 62, pp. 722–728, 2002.
, “2,3,7,8-Tetrachlorodibenzo-p-dioxin Affects the Number and Function of Murine Splenic Dendritic Cells and Their Expression of Accessory Molecules”, Toxicology and Applied Pharmacology, vol. 171, no. 2, pp. 117 - 125, 2001.
, “ Advertisement In utero Exposure of Mice to Dibenzo[a,l]Pyrene Produces Lymphoma in the Offspring: Role of the Aryl Hydrocarbon Receptor ”, Journal of Immunotoxicology, vol. 5, no. 1, pp. 81 - 91, 2008.
, , “Anti-CD40 Treatment of 2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD)-Exposed C57Bl/6 Mice Induces Activation of Antigen Presenting Cells Yet Fails to Overcome TCDD-Induced Suppression of Allograft Immunity”, Toxicology and Applied Pharmacology, vol. 170, no. 1, pp. 10 - 22, 2001.
, “The anti-inflammatory drug leflunomide is an agonist of the aryl hydrocarbon receptor”, PLoS One, vol. 5, p. e13128, 2010.
“Aryl Hydrocarbon Receptor-Deficient Mice Generate Normal Immune Responses to Model Antigens and Are Resistant to TCDD-Induced Immune Suppression”, Toxicology and Applied Pharmacology, vol. 171, no. 3, pp. 157 - 164, 2001.
, ,
“Contrasting the roles of costimulation and the natural adjuvant lipopolysaccharide during the induction of T cell immunity”, The Journal of Immunology, vol. 168, pp. 4372–4381, 2002.
, “CTL Hyporesponsiveness Induced by 2,3,7,8-Tetrachlorodibenzo-p-dioxin: Role of Cytokines and Apoptosis”, Toxicology and Applied Pharmacology, vol. 166, no. 3, pp. 214 - 221, 2000.
, “Cutting edge: activation of the aryl hydrocarbon receptor by 2,3,7,8-tetrachlorodibenzo-p-dioxin generates a population of CD4+ CD25+ cells with characteristics of regulatory T cells.”, J Immunol, vol. 175, no. 7, pp. 4184-8, 2005.
, “Dibenzo[a,l]pyrene induced DNA adduct formation in lung tissue in vivo”, Cancer Letters, vol. 227, no. 1, pp. 25 - 32, 2005.
, “Dibenzo[a,l]pyrene induced DNA adduct formation in lung tissue in vivo.”, Cancer Lett, vol. 227, no. 1, pp. 25-32, 2005.
, “Early Consequences of 2,3,7,8-Tetrachlorodibenzo-p-dioxin Exposure on the Activation and Survival of Antigen-Specific T Cells”, Toxicological Sciences, vol. 82, no. 1, pp. 129 - 142, 2004.
, “Functional alterations in CD11b(+)Gr-1(+) cells in mice injected with allogeneic tumor cells and treated with 2,3,7,8-tetrachlorodibenzo-p-dioxin.”, Int Immunopharmacol, vol. 3, no. 4, pp. 553-70, 2003.
, “Influence of 2,3,7,8-Tetrachlorodibenzo-p-dioxin on the Antigen-Presenting Activity of Dendritic Cells”, Toxicological Sciences, vol. 72, no. 1, pp. 103 - 112, 2003.
, “Mechanism of 2, 3, 7, 8-tetrachlorodibenzo-p-dioxin (TCDD)-induced decrease in anti-CD3-activated CD4+ T cells: the roles of apoptosis, Fas, and TNF”, Toxicology, vol. 170, pp. 139–151, 2002.
, “Modeling of the Aryl Hydrocarbon Receptor (AhR) Ligand Binding Domain and Its Utility in Virtual Ligand Screening to Predict New AhR Ligands”, Journal of Medicinal Chemistry, vol. 52, no. 18, pp. 5635 - 5641, 2009.
, “Recent advances in understanding the mechanisms of TCDD immunotoxicity.”, Int Immunopharmacol, vol. 2, no. 2-3, pp. 277-91, 2002.
, “A structural switch between agonist and antagonist bound conformations for a ligand-optimized model of the human aryl hydrocarbon receptor ligand binding domain”, Biology, vol. 3, pp. 645–669, 2014.
, “A Structural Switch between Agonist and Antagonist Bound Conformations for a Ligand-Optimized Model of the Human Aryl Hydrocarbon Receptor Ligand Binding Domain”, Biology, vol. 399, no. 4, pp. 645 - 669, 2014.
, “T Lymphocytes Are Direct, Aryl Hydrocarbon Receptor (AhR)-Dependent Targets of 2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD): AhR Expression in Both CD4+ and CD8+ T Cells Is Necessary for Full Suppression of a Cytotoxic T Lymphocyte Response by TCDD”, Toxicology and Applied Pharmacology, vol. 185, no. 2, pp. 146 - 152, 2002.
,